Thymosin Alpha 1 vs VIP (Vasoactive Intestinal Peptide)

Thymosin Alpha 1

Thymosin alpha 1 is a 28-residue peptide, acetylated at its N-terminus, first isolated from calf thymus extract and now made synthetically. It matches the N-terminal segment of a larger protein, prothymosin alpha, from which it is thought to be released by proteolytic processing; the synthetic form is also known as thymalfasin. The peptide is strongly acidic and, in water, largely unstructured. Its literature spans cell studies of immune signalling, animal infection and tumour models, and human clinical studies in chronic viral hepatitis, severe infection and vaccine response. Many of those clinical studies are small, and a defined cellular receptor has not been confirmed.

VIP (Vasoactive Intestinal Peptide)

VIP, or vasoactive intestinal peptide, is a 28-residue amidated neuropeptide found in central and peripheral neurons and in the gut wall. It belongs to the secretin–glucagon family and is most closely related to pituitary adenylate cyclase-activating polypeptide (PACAP), with which it shares receptors. First isolated from intestinal tissue and named for its action on blood vessels, it is now studied as a neurotransmitter, a smooth-muscle signal and a messenger between the nervous and immune systems. Most of the literature comes from cell, tissue and animal studies. Synthetic VIP has been examined in small human studies, including in pulmonary conditions, but it is cleared from the circulation within a few minutes, which complicates that work.

How Thymosin Alpha 1 acts

Thymosin alpha 1 has no single confirmed receptor. Several studies have linked its activity to Toll-like receptor signalling, particularly TLR9 and TLR2 in dendritic cells, with downstream activation of pathways including NF-κB and p38 MAPK. In cell and animal models it has been reported to influence T-cell maturation, production of cytokines such as interleukin-2 and interferon-gamma, and natural killer cell activity. Structural studies report that it becomes partly helical in membrane-like environments, which has been proposed as relevant to how it interacts with cells, though this remains an open question.

How VIP (Vasoactive Intestinal Peptide) acts

VIP binds two class B G-protein-coupled receptors, VPAC1 and VPAC2, with similar affinity, and binds the PACAP-preferring PAC1 receptor much more weakly. Both VPAC receptors couple mainly to Gs, raising cyclic AMP and activating protein kinase A, although coupling to other G proteins has been described. In immune cell cultures this signalling has been reported to alter cytokine production and T-cell differentiation. In the suprachiasmatic nucleus, mouse studies indicate that VIP acting at VPAC2 helps synchronise the neurons of the circadian clock. In smooth muscle preparations it has been examined as a relaxant signal.

The records side by side

• Type: Thymosin Alpha 1, Acetylated thymic peptide; VIP (Vasoactive Intestinal Peptide), Neuropeptide (vasoactive intestinal peptide)
• Length: Thymosin Alpha 1, 28 amino acids; VIP (Vasoactive Intestinal Peptide), 28 amino acids
• Molecular weight: Thymosin Alpha 1, 3108.3 g/mol; VIP (Vasoactive Intestinal Peptide), 3326.8 g/mol
• Molecular formula: Thymosin Alpha 1, C129H215N33O55; VIP (Vasoactive Intestinal Peptide), C147H237N43O43S

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.